Internal Medicine Alert – January 30, 2020
January 30, 2020
View Issues
-
Menopausal Hormonal Therapy and Breast Cancer Risk: Are Old Data Relevant to Today’s Practice?
An individual-participant meta-analysis of prospective studies revealed menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.
-
Dapagliflozin Treatment Improves Life Quality for Systolic Heart Failure Patients
Treatment with dapagliflozin for 12 weeks resulted in improved health status, either a reduction in NT-proBNP or improvement in quality of life measures, in systolic heart failure patients with or without type 2 diabetes mellitus.
-
What Is the Optimal Blood Pressure for Secondary Prevention of Stroke?
Investigators terminated a study early before they could draw any firm conclusions. Thus, there remains a lack of solid evidence to support a firm recommendation regarding optimal blood pressure management for secondary stroke prevention.
-
Stable Coronary Disease and Atrial Fibrillation Patients Best Treated With Rivaroxaban Alone
Monotherapy with rivaroxaban was noninferior to combination therapy for the primary efficacy endpoint of composite of stroke, systemic embolism, myocardial infarction, unstable angina, or death from any cause.
-
Lemborexant Tablets (Dayvigo)
Lemborexant should be prescribed to treat adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.